Kiromic BioPharma (KRBP)

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	3.06 mm	3.06 mm	3.06 mm	3.06 mm	3.06 mm	3.06 mm
Cash burn (monthly)	206.67 k	(no burn)	2.20 mm	1.88 mm	(no burn)	1.36 mm
Cash used (since last report)	582.13 k	n/a	6.20 mm	5.30 mm	n/a	3.83 mm
Cash remaining	2.47 mm	n/a	-3.14 mm	-2.25 mm	n/a	-778.40 k
Runway (months of cash)	12.0	n/a	-1.4	-1.2	n/a	-0.6

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q2 2023

KRBP institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	6	9	-33.3%
Opened positions	0	2	EXIT
Closed positions	3	7	-57.1%
Increased positions	0	0
Reduced positions	2	5	-60.0%

13F shares	Current	Prev Q	Change
Total value	6.66 mm	72.77 mm	-90.8%
Total shares	2.18 mm	2.20 mm	-0.8%
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
YA II PN	1.69 mm	$542.00 k	0.0%
Empery Asset Management	491.55 k	$0.00	0.0%
Tower Research Capital	1.40 k	$3.81 mm	-10.3%
BLK BlackRock	809.00	$2.20 mm	0.0%
MS Morgan Stanley	40.00	$109.00 k	0.0%
Group One Trading	1.00	$3.00 k	-87.5%
Proequities	0.00	$0.00

Largest transactions	Shares	Bought/sold	Change
Susquehanna International	0.00	-16.46 k	EXIT
UBS UBS	0.00	-1.22 k	EXIT
Tower Research Capital	1.40 k	-160.00	-10.3%
Group One Trading	1.00	-7.00	-87.5%
WFC Wells Fargo & Company	0.00	-4.00	EXIT
Proequities	0.00	0.00
MS Morgan Stanley	40.00	0.00	0.0%
BLK BlackRock	809.00	0.00	0.0%
YA II PN	1.69 mm	0.00	0.0%
Empery Asset Management	491.55 k	0.00	0.0%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

KRBP insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
26 Aug 24	Pietro Bersani	Common Stock	Buy	Acquire P	No	No	1.93	988	1.91 k	142,333
23 Aug 24	Pietro Bersani	Common Stock	Buy	Acquire P	No	No	2.2	2,500	5.50 k	141,345
20 Aug 24	Brian Hungerford	Common Stock	Buy	Acquire P	No	No	2.197	3,742	8.22 k	64,933
19 Aug 24	Brian Hungerford	Common Stock	Buy	Acquire P	No	No	2.25	258	580.50	61,191
13 Aug 24	Brian Hungerford	Common Stock	Buy	Acquire P	No	No	1.75	2,000	3.50 k	60,933
13 Jun 24	Brian Hungerford	Common Stock	Buy	Acquire P	No	No	2.6	1,000	2.60 k	58,933
12 Jun 24	Brian Hungerford	Common Stock	Buy	Acquire P	No	No	3.18	1,000	3.18 k	57,933

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

Financial Crime Weekly: CEO Sentenced To 51 Months In Prison, Kiromic BioPharma Charged With Failure To Disclose Material Information

7 Dec 24

A CEO is sentenced to 51 months in prison for fraud and ordered to pay $6.1 million in restitution. Kiromic BioPharma is charged with failure to disclose material information.

Press releases

From Benzinga Pro

Kiromic BioPharma Reports 32% Decrease in Tumor Volume Eight Months Post-Treatment in Fourth Patient Enrolled in Deltacel-01

12 Dec 24

Kiromic BioPharma, Inc. (OTCQB:KRBP) ("Kiromic" or the "Company") reports favorable ongoing efficacy results from the eight-month follow-up visit for the fourth patient enrolled in its Deltacel-01 Phase 1 clinical

Kiromic BioPharma Announces Settlement of Previously Disclosed SEC Investigation

3 Dec 24

SEC declines to impose civil penalties in light of the Company's self-reporting, prompt remediation and cooperation Kiromic BioPharma, Inc. (OTCQB:KRBP) ("Kiromic" or the "Company") today announced that it has entered